Limits...
Prophylactic cranial irradiation for patients with small-cell lung cancer: a systematic review of the literature with meta-analysis.

Zhang W, Jiang W, Luan L, Wang L, Zheng X, Wang G - BMC Cancer (2014)

Bottom Line: Small cell lung cancer (SCLC) accounts for about 13% of all lung cancer cases.Methodological quality was assessed with the Jadad scale.The main end points were brain metastasis and survival.

View Article: PubMed Central - PubMed

Affiliation: School of Nursing, Shandong University, Jinan 250012, China. wanggongchao@126.com.

ABSTRACT

Background: Small cell lung cancer (SCLC) accounts for about 13% of all lung cancer cases. Small cell lung cancer (SCLC) accounts for about 13% of all lung cancer cases. The purpose of the present article is to assess the role of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC) by performing a systematic review of the randomized trials published in the literature.

Methods: Randomized controlled trials were identified that compared brain metastases incidence and overall survival between PCI and No PCI in patients with SCLC. Search strategies were limited to the English language and to articles published since 1997, and included: databases searched from 1997 to March 2013 -CINAHL, Embase, Medline, Web of Science, and CENTRAL. Methodological quality was assessed with the Jadad scale. The main end points were brain metastasis and survival.

Results: The review identified 5 trials, although few were of high quality. Two trials reported the one-year incidence of brain metastasis. PCI reduced the incidence of brain metastasis in one year, with a pooled relative risk of 0.45 (95% CI, 0.35 to 0.58; P < 0.00001). Four trials described the one year survival rate. The combined result revealed a significant (P = 0.01) survival benefit in the group assigned to PCI as compared with the control group, with a pooled relative risk of 0.87 (95% CI, 0.79 to 0.97). Three trials reported the three-year survival rate. The combined result revealed a great significant (P < 0.00001) survival benefit in the PCI group as compared with the No PCI group, with a pooled relative risk of 0.87 (95% CI, 0.83 to 0.91). the Five-year survival rate was compared in four trials Compared with the No PCI group, the PCI group had a significant (P < 0.00001) survival benefit with a pooled relative risk of 0.92 (95% CI, 0.88 to 0.95).

Conclusions: The present systematic review indicates that PCI decreases brain metastases incidence and that PCI improves survival in SCLC patients. Prophylactic cranial irradiation should be part of standard care for all patients with small-cell lung cancer who have a response to initial chemotherapy, and it should be part of the standard treatment in future studies involving these patients.

Show MeSH

Related in: MedlinePlus

Relative-risk plots for brain metastasis of 1 year.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4232715&req=5

Fig1: Relative-risk plots for brain metastasis of 1 year.

Mentions: Three trials reported the one-year incidence of brain metastasis. But we included two eligible trials. If Cao KJ’s study was included, the heterogeneity would exist among the trials. So we excluded it. As shown in the Figure 1, PCI reduced the incidence of brain metastasis in one year, with a pooled relative risk of 0.45 (95% CI, 0.35 to 0.58; P < 0.00001).Figure 1


Prophylactic cranial irradiation for patients with small-cell lung cancer: a systematic review of the literature with meta-analysis.

Zhang W, Jiang W, Luan L, Wang L, Zheng X, Wang G - BMC Cancer (2014)

Relative-risk plots for brain metastasis of 1 year.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4232715&req=5

Fig1: Relative-risk plots for brain metastasis of 1 year.
Mentions: Three trials reported the one-year incidence of brain metastasis. But we included two eligible trials. If Cao KJ’s study was included, the heterogeneity would exist among the trials. So we excluded it. As shown in the Figure 1, PCI reduced the incidence of brain metastasis in one year, with a pooled relative risk of 0.45 (95% CI, 0.35 to 0.58; P < 0.00001).Figure 1

Bottom Line: Small cell lung cancer (SCLC) accounts for about 13% of all lung cancer cases.Methodological quality was assessed with the Jadad scale.The main end points were brain metastasis and survival.

View Article: PubMed Central - PubMed

Affiliation: School of Nursing, Shandong University, Jinan 250012, China. wanggongchao@126.com.

ABSTRACT

Background: Small cell lung cancer (SCLC) accounts for about 13% of all lung cancer cases. Small cell lung cancer (SCLC) accounts for about 13% of all lung cancer cases. The purpose of the present article is to assess the role of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC) by performing a systematic review of the randomized trials published in the literature.

Methods: Randomized controlled trials were identified that compared brain metastases incidence and overall survival between PCI and No PCI in patients with SCLC. Search strategies were limited to the English language and to articles published since 1997, and included: databases searched from 1997 to March 2013 -CINAHL, Embase, Medline, Web of Science, and CENTRAL. Methodological quality was assessed with the Jadad scale. The main end points were brain metastasis and survival.

Results: The review identified 5 trials, although few were of high quality. Two trials reported the one-year incidence of brain metastasis. PCI reduced the incidence of brain metastasis in one year, with a pooled relative risk of 0.45 (95% CI, 0.35 to 0.58; P < 0.00001). Four trials described the one year survival rate. The combined result revealed a significant (P = 0.01) survival benefit in the group assigned to PCI as compared with the control group, with a pooled relative risk of 0.87 (95% CI, 0.79 to 0.97). Three trials reported the three-year survival rate. The combined result revealed a great significant (P < 0.00001) survival benefit in the PCI group as compared with the No PCI group, with a pooled relative risk of 0.87 (95% CI, 0.83 to 0.91). the Five-year survival rate was compared in four trials Compared with the No PCI group, the PCI group had a significant (P < 0.00001) survival benefit with a pooled relative risk of 0.92 (95% CI, 0.88 to 0.95).

Conclusions: The present systematic review indicates that PCI decreases brain metastases incidence and that PCI improves survival in SCLC patients. Prophylactic cranial irradiation should be part of standard care for all patients with small-cell lung cancer who have a response to initial chemotherapy, and it should be part of the standard treatment in future studies involving these patients.

Show MeSH
Related in: MedlinePlus